Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.42 |
| ▸ | THRA | P10827 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 3/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5592573 | 0.90 | MEN1 (0.49) | CCNCCDK8EPHB4MAPTKDM4E | |
| SCHEMBL5586067 | 0.89 | NAMPT (0.44) | EPHB4THRATHRBMAPTNAMPT | |
| SCHEMBL5612270 | 0.88 | MAPT (0.48) | EPHB4MAPTKDM4EALDH1A1GAA | |
| SCHEMBL5592683 | 0.86 | EPHB4 (0.53) | EPHB4NAMPTTRPV1 | |
| SCHEMBL5611827 | 0.84 | EPHB4 (0.45) | EPHB4THRATHRBMAPTALDH1A1 | |
| SCHEMBL5586132 | 0.83 | MEN1 (0.57) | EPHB4MAPTKDM4EALDH1A1GAA | |
| SCHEMBL5592847 | 0.82 | MEN1 (0.56) | MAPTALDH1A1NAMPTTRPV1MEN1 | |
| SCHEMBL5602071 | 0.81 | HTR2C (0.54) | EPHB4MAPTKDM4EALDH1A1GAA | |
| SCHEMBL5611432 | 0.81 | THRA (0.41) | EPHB4THRATHRBKDM4EALDH1A1 | |
| SCHEMBL5592922 | 0.80 | RAB9A (0.58) | THRBMAPTKDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858879-B1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | GILEAD CONNECTICUT INC (US) | 2012-06-06 | — | — | EP | claimed |
| CN-102267978-A | 1,3-diaryl substituted ureas as modulators of kinase activity | — | 2011-12-07 | — | — | CN | claimed |
| CN-101163691-A | 1, 3-diaryl substituted ureas as modulators of kinase activity | CGI PHARMACEUTICALS INC (US) | 2008-04-16 | — | — | CN | claimed |
| US-20060199846-A1 | Certain substituted ureas as modulators of kinase activity | GILEAD CONNECTICUT, INC. | 2006-09-07 | — | — | US | claimed |
| EP-1858879-B1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | GILEAD CONNECTICUT INC (US) | 2012-06-06 | — | — | EP | disclosed |
| EP-2397478-A1 | 1,3-diaryl substituted ureas as modulators of kinase activity. | CGI Pharmaceuticals, Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| CN-102267978-A | 1,3-diaryl substituted ureas as modulators of kinase activity | — | 2011-12-07 | — | — | CN | disclosed |
| CN-101163691-A | 1, 3-diaryl substituted ureas as modulators of kinase activity | CGI PHARMACEUTICALS INC (US) | 2008-04-16 | — | — | CN | disclosed |
| EP-1858879-A1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | CGI Pharmaceuticals, Inc. (US) | 2007-11-28 | — | — | EP | disclosed |
| US-20060199846-A1 | Certain substituted ureas as modulators of kinase activity | GILEAD CONNECTICUT, INC. | 2006-09-07 | — | — | US | disclosed |
| WO-2006076593-A1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| WO-1995004160-A1 | TAG REAGENT AND ASSAY METHOD | ISIS INNOVATION LIMITED (GB) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199846-A1 | Certain substituted ureas as modulators of kinase activity | UCK2, CHUK, AXL | CCNC 253/4885CDK8 57/4885EPHB4 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.